Roche Oligonucleotides for Paternal UBE3A Expression

The EPO granted patent EP3798307A1 to F. Hoffmann-La Roche AG for oligonucleotides that induce paternal UBE3A expression. The patent covers compositions and methods using synthetic nucleic acids to reactivate the paternal UBE3A allele, relevant to Angelman syndrome and similar genetic disorders. Inventors include Costa, Hedtjarn, Hoener, Jagasia, Jensen, and Pedersen among others.

For biotechnology and pharmaceutical companies developing genetic medicines, this patent establishes intellectual property protection around UBE3A modulation approaches. Companies pursuing gene reactivation therapies should conduct freedom-to-operate analyses and consider licensing negotiations with Roche. The broad designation of 39 EPC contracting states creates significant territorial coverage for the patented technology.